Shamis & Gentile, P.A. is investigating claims on behalf of investors of Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX). Impacted investors are advised to contact the firm now.
The investigation concerns whether Nutex Health and some of its top management engaged in securities fraud or other misconduct. The current focus is on Company statements regarding the source and sustainability of its revenue growth during the period from July 1, 2024 through July 23, 2025. Throughout this period, Nutex Health’s management seemingly attributed significant revenue increases to its arbitration strategy under the No Surprises Act.
On July 22, 2025, Blue Orca Capital released a report alleging that Nutex Health’s growth was driven by a questionable arbitration strategy enabled by HaloMD, which was cited in federal lawsuits for fraud and racketeering. The report raised significant doubts about the legitimacy of Nutex Health’s reported revenue gains.
On this news, Nutex Health’s stock price fell approximately 10% on July 22, 2025, and an additional 7% on July 23, 2025, closing at $92.90 per share. The two-day decline erased over $450 million in market capitalization, with the stock dropping from a peak of around $176 to $92.90 per share.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise, and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.
Attorney advertising. Prior results do not guarantee similar outcomes.
